BioNxt Solutions Inc. (BNXTF)

Market Cap	86.81M
Revenue (ttm)	15.90K
Net Income (ttm)	-3.97M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,409
Open	0.7500
Previous Close	0.7500
Day's Range	0.7500 - 0.7500
52-Week Range	0.1116 - 0.8000
Beta	1.54
RSI	66.71
Earnings Date	Aug 27, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: BNXTF

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial numbers in CAD